Merck CEO warns price controls could hamper drug innovation, FT says

As Democrats propose using Medicare to negotiate lower drug prices as part of a deficit solution, Merck's (MRK) CEO Ken Frazier warned about the potential for price controls to stifle innovation and eliminate the economic incentive to invest in R&D, reported Financial Times.

View Comments (1)